Radiation Cystitis

7

Review clinical trials related to Radiation Cystitis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Chronic Radiation Cystitis and Effect of Hyperbaric Oxygen Therapy on Patient Reported Outcomes and Urine Inflammatory Biomarkers

Collection of urine, blood, and tissue samples from patients undergoing hyperbaric oxygen therapy

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Rachel A. MosesUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

At least 18 years of age [+9]

Pregnant or lactating (females will be asked if there is any chance they could b... [+4]

Status: Not yet recruiting

Clinical Efficacy of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Combined With Sodium Hyaluronate Intravesical Instillation in the Treatment of Radiation Cystitis

The goal of this clinical trial is to learn whether intravesical instillation of human umbilical cord mesenchymal stem cell-derived exosomes combined with sodium hyaluronate is safe and effective for treating radiation cystitis. Radiation cystitis is a complication that may occur after pelvic radiotherapy. Common symptoms include blood in the urine, frequent urination, urgent urination, and painful urination. The main questions this study aims to answer are: Can human umbilical cord mesenchymal stem cell-derived exosomes combined with sodium hyaluronate improve blood in the urine in participants with radiation cystitis? Can this combined treatment help repair injury to the bladder lining and blood vessels? What discomfort or medical problems may occur during the treatment? Researchers will compare four treatment approaches: human umbilical cord mesenchymal stem cell-derived exosomes combined with sodium hyaluronate, human umbilical cord mesenchymal stem cell-derived exosomes alone, sodium hyaluronate alone, and normal saline as a control. By comparing these groups, researchers hope to find out whether the combined treatment works better than either treatment alone or the control treatment. Participants will: Be screened to confirm whether they are eligible for the study; Sign an informed consent form and complete baseline assessments; Be randomly assigned to one of four treatment groups; Receive intravesical instillation once a week for 4 weeks; Attend follow-up visits at 1 month, 3 months, and 6 months after treatment; Be assessed for blood in the urine, urinary symptoms, cystoscopy findings, quality of life, and safety. This study may help provide a new treatment option for radiation cystitis and further evaluate the safety and early effectiveness of this treatment.

Participants needed: 48
Trial details
Phase: Early Phase 1Age: 18-80Biological sex: FemaleType: InterventionalSponsor: Fujian Medical University Union HospitalUpdated: Jun 24, 2026
Eligibility criteria

Female participants aged 18-80 years. [+3]

Acute urinary tract infection or active tuberculous cystitis. [+5]

Status: Recruiting

Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients With Chronic Atrial Fibrillation and Radiation Cystitis at Risk of Bleeding

The etiology of the radiation cystitis is a pelvic irradiation generally performed as part of the treatment of prostate cancer. The incidence is 50,000 new cases per year. Approximately 35% of prostate cancer treatment is radiotherapy. The prevalence of haematuric radiation cystitis is 4-5% (about 800 patients). One of the complications of radiation cystitis is persistent hematuria. There is currently no curative treatment for this hematuria. There are few treatment options with a random probability of improvement of this symptomatology. These haematurias are rarely resolved spontaneously and most of the time involve emergency room management with +/- invasive procedures, sometimes by hospitalisation, always with a significant psychological impact on the patient. Furthermore, lifetime anticoagulant treatment considerably increases the likelihood of bladder bleeding. This is the case of patients being followed for Atrial Fibrillation Cardiac Arrhythmia (AFCA), which by definition carries a major cardioembolic risk, and who will be of particular interest in this study. In recent years, cardiologists have developed an alternative to anticoagulants: left atrial appendage closure or left atrial occlusion (LAO) . This procedure consists of inserting a nitinol prosthesis in the left atrium, the site of more than 90% of thrombi formation in non-valvular atrial fibrillation. This minimally invasive procedure lasts about 15 minutes and is performed during a 48-hour hospitalization. Anticoagulants are stopped the day after the setting up procedure. Several studies have shown non-inferiority of atrial closure and anticoagulants to thromboembolic events in non-valvular atrial fibrillation. In addition, LAO allows the permanent discontinuation of anticoagulants, associated with the cessation of anticoagulant bleeding adverse events. While studies have been conducted on the impact of this technique on patients monitored in cardiology, no studies evaluate the value of LAO in anticoagulated patients with a hematuric radiation cystitis. This tprocedure is already used in routine care for patients followed in urology, and has shown encouraging results, since 8 out of 10 patients saw a significant reduction in the number of haematurias, but it has never yet been scientifically proven to be effective, hence the aim of this study. The interest of this study will therefore be : * To evaluate the potential benefit of left atrial appendage closure on the number of episodes of hematuria. * To evaluate the economic benefit in reducing the number of hospitalizations, surgeries and complications for hematuria as well as the discontinuation of anticoagulants. As the patient's data must be retrieved regardless of the patient's subsequent management (with or without a cardiac procedure) within the framework of the HEMOCC protocol, it will be proposed to the patient as soon as he or she is consulting for haematuria on radiation cystitis. The patient will be followed for 3 years. The mainly descriptive analyses will be collected in the form of a register and carried out by a biostatistician from Clermont-Ferrand University Hospital.

Participants needed: 40
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: University Hospital, Clermont-FerrandUpdated: Mar 19, 2026Locations: 1
Eligibility criteria

Patient over 18 years old benefiting a social security sheme. [+1]

All the other hematuria's reasons [+1]

Status: Recruiting

Chronic Radiation Cystitis and Effect of Hyperbaric Oxygen Therapy on Patient Reported Outcomes and Urine Inflammatory Biomarkers

Collection of urine, blood, and tissue samples from patients undergoing hyperbaric oxygen therapy

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Rachel A. MosesUpdated: Jan 26, 2026Locations: 1
Eligibility criteria

At least 18 years of age [+9]

Pregnant or lactating (females will be asked if there is any chance they could b... [+4]

Status: Not yet recruiting

Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox)

Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.

Participants needed: 38
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Bernardino Clavo, MD, PhDUpdated: Dec 22, 2025Locations: 2Duration: 4 Months
Eligibility criteria

Adult women (>=18 years). [+5]

Not meeting all inclusion criteria. [+3]

Status: Not yet recruiting

Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer

To evaluate the efficacy and safety of intravesical hyaluronic acid (HA) instillation therapy for the prevention of radiation-induced cystitis in patients undergoing radiotherapy for bladder cancer.

Participants needed: 54
Trial details
Age: 19+Biological sex: AllType: InterventionalSponsor: National Cancer Center, KoreaUpdated: Aug 15, 2025Locations: 1
Eligibility criteria

Pathologic confirmed Muscle-Invasive Urothelial Carcinoma I. Clinical stage: T2-... [+5]

Present of distant metastasis (M1) [+7]

Status: Recruiting

Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial

The purpose of this study is to evaluate the efficacy and safety of pentosan polysulfate sodium versus placebo and in patients with radiation cystitis who have received radiation therapy in pelvic region.

Participants needed: 72
Trial details
Phase: Phase 2, Phase 3Age: 20+Biological sex: AllType: InterventionalSponsor: National Taiwan University HospitalUpdated: May 4, 2022Locations: 1
Eligibility criteria

Capable of giving signed informed consent, which includes compliance with the re... [+4]

Abnormal liver function with indication of AST, ALT, or total bilirubin ≥ 1.5 ti... [+13]